Sumnmay-Epidermal growth factor receptor (EGFR) has been the subject of much research since it was first described as a prognostic factor in breast cancer. The assay methods used and results obtained vary widely between studies. In this study 88 primary breast cancers were assayed for EGFR using a novel immunohistochermcal assay performed on paraffin-embedded sections. The monoclonal antibody used was raised against purified, denatured EGFR, reacts with an epitope on the external domain and does not interfere with ligand binding. Twenty-two per cent of the tumours were EGFR positive using this assay. The results obtained were significantly correlated with those obtained by ligand-binding assay (r= 0.621. P= 0.011). The concordance rate was 82%(P<0.0001). The majority of discordant results could be explained by the presence of benign breast tissue and other non-malignant elements which could be seen to express EGFR on the immunohistochemical assay and were excluded from the score for this, but would be incorporated into ligand-binding assay results. The well-established inverse relationship between EGFR (as measured by this assay) and oestrogen receptor (ER) was seen (Q=24.9. P<0.0001). In addition, in this exploratory study on a limited tumour set. EGFR was a significant adverse prognostic factor (on umnvariate but not multivariate analysis) for both relapse-free survival (P= 0.02) and overall survival (P= 0.03) when measured by this immunohistochemical assay. but was not significant when measured by ligand-binding assay.
EGFR is a 170 kDa cell-surface receptor with an external domain containing the ligand-binding region, a short transmembrane domain and an intracellular domain containing a region with tyrosine kinase activity. It is one of an expanding group of homologous transmembrane receptors with tyrosine kinase activity which currently comprises EGFR, c-erb B-2, c-erb B-3 and recently c-erb BA4 (Carraway and Cantley, 1994; Rajkumar and Gullick, 1994) . EGFR has a number of ligands, including epidermal growth factor (EGF), transforming growth factor alpha, amphiregulin, cripto and heparinbinding EGF. EGFR is present on a number of benign and malignant human cell lines, including some human breast cancer cell lines. In vitro, EGFR and its ligands have been implicated in malignant transformation via autocrne and paracrine growth factor pathways (Normanno et al., 1994) . In vivo, EGFR is expressed in a number of human tissues, both normal and malignant. Among cancers, EGFR is most strongly expressed in squamous cell carcinomas, but it is also found in a variety of other tumours, including approximately 45% of breast adenocarcinomas (Klijn et al., 1992) . A number of studies have shown it to be an adverse prognostic factor in breast cancer (Sainsbury et al., 1987; Costa et al., 1988; Harris et al., 1989; Lewis et al., 1990; Spyratos et al., 1990; Nicholson et al., 1991; Toi et al., 1991; Gasparini et al., 1992; Koenders et al., 1993; Fox et al., 1994) , though this is not confirmed in all such studies (Foekens et al., 1989; Coombes et al., 1990; Murray et al., 1993; reviewed in Klijn et al., 1992; Fox et al., 1994) . In contrast, the literature is consistent in reporting an inverse relationship between EGFR and ER (reviewed in Klijn et al., 1992) . EGFR has also been shown to be an indicator of a poor chance of response to endocrine therapy (Nicholson et al., 1988a; Harris et al., 1989; Nicholson et al., 1994) .
A number of assays have been used to measure EGFR, of which the most widely applied is the ligand-binding assay (LBA) (Nicholson et al., 1988b EGFR-associated phosphotyrosine kinase activity (BaugnetMahieu and Lemaire, 1990) .
Ligand-binding assay is generally accepted as the 'gold standard' in EGFR measurements, though even here there is disagreement about the cut-off used to define positivity (Klijn et al., 1992) . Immunohistochemical assays (IHAs) are simple to perform, can be semiquantitative and have the advantage over LBA of showing the tissue distnrbution of EGFR. However, there are two major problems with the IHAs descnrbed in the literature. Firstly, the majonrty do not work on paraffin-embedded material and so cannot be applied to archival material. Secondly, few studies have attempted to validate the assays used. In addition some anti-EGFR antibodies are raised against receptor in glycosylated form. These will potentially cross-react with blood group antigens and make interpretation of results difficult (Gerdin et al.. 1992) . Care must therefore be taken to ensure that the antibody used (in any assay method) is raised against epitopes on the EGFR protein and not on associated carbohydrate moieties.
We have developed an immunohistochemical assay for EGFR which works on paraffin-embedded sections and have validated this on a tumour set for which EGFR had previously been measured by ligand-binding assay. To find a clinically relevant cut-off point for this assay, analysis of the prognostic significance was deterniined for all possible values. The expected relationship with ER status was also assessed. (Figure 2 ).
Definition of positivitY for EGFR
A discriminatory value for EGFR(IHA) positivity was optimised by continuous testing across the range of all possible values in relation to prognosis (relapse-free and overall survival). The value selected was that which was associated with the greatest statistical significance for the comparison between the two groups it defined. For EGFR(IHA) this gave an optimal cut-off of 35. with 22% of the cases defined as positive. This compared with 44% of cases positive for EGFR(LBA) using the conventional cut-off of > 20 fmol mg-' protein.
Optimising the cut-off for the EGFR(LBA) data gave a cut-off value of approximately 80 fmol mg-'. defining only 12% of cases as positive. This was too small a group on which to perform meaningful survival analysis. To allow a valid comparison between the prognostic significance of the two methods, an alternative approach was taken: a cut-off for EGFR(LBA) which defined the same proportion (22%) of cases as positive as the optimised EGFR(IHA) was found. This gave a cut-off of 38 fmol mg-'. The different cut-offs are referred to below as EGFR(LBA-20) and EGFR (Figure 3) , it can be seen that the majority of the cases with discordant results were negative on immunostaining but positive to a variable degree on LBA. It is probably significant that, of the 25 cases which were negative for EGFR (IHA) but positive for EGFR . 16 sections also contained some benign breast epithelium, and in 14 of these 16 cases the benign epithelial elements were positive for EGFR. The intensity of staining in benign breast epithelium was similar to that seen in malignant epithelium. When the optimised LBA cut-off (LBA-38) was applied, the concordance increased to 82% (P<0.0001). It can be seen from Figure 3 that the improved concordance using EGFR (LBA-38) is largely due to the loss from the relationship of cases which were IHA negative but LBA-20 positive.
Association with other parameters No association was found between EGFR measured by either method and patient age or tumour size. Table I shows the number of EGFR-positive cases divided according to number of nodes involved for both assay methods. The expected inverse relationship with ER exists for EGFR as measured by IHA (X: = 24.9, P<0.0001) and for EGFR (LBA-38)(j = 8.3, P = 0.0071), though it is not significant for EGFR (LBA-20) (Table I ). Only two tumours were positive for both EGFR (IHA) and ER. Prognostic value Table II shows the results of univanrate analysis of prognostic factors for this set of patients. It can be seen that, while nodal status was the most powerful prognostic factor of those analysed, size 2.5 cm (P = 0.01), ER status (P = 0.05) and EGFR (IHA) (P = 0.02) were all significant Some studies have compared the results of LBA and IHA assays for EGFR In their orginal study, Sainsbury et al. (1985) found that results obtained by immunostaining with the EGFR-1 antibody on frozen sections 'correlated with' the results of ligand-binding assay. In a more formal comparison, Toi et al. (1989) found a 94% concordance between immunotaining with the EGFR-1 antibody and results of ligand-binding assay. Using the same antibody in ovarian carcnomas, a concordance of 67% was found between the two methods (Owens et al., 1992) . Using a different antibody, MAb 425, on breast cancers, no signint differences wer seen when EGFR which had been measured both biochemically and immunohistochemialy was indeently correlated with other tumour characteristis, but this study did not directly compare the two assay results (Becinman et al., 1993) . All of the above immunohistochemical studies were performed on frozen sections. A recent study has compared LBA, EIA and IHA and found reasonable agreement between the results of the three methods (72% concordance between IHA and LBA) (Iwase et al., 1993) . That study concluded that EIA is the most appropriate method for use with clinical samples on the basis that it had the strongest prognostic value in the patient group examined. None of the IHAs described in these studies were conducted on paraffinembedded sections, a procedure which has been difficult to perform successfully for EGFR. The availability of such an assay would be extremely valuable in the investigation of the biological/clical signifia of EGFR in the enormous stores of archival pathological material.
We have descibed and validated an immunohistochemical assay for EGFR which works on formalin-fixed, paraffin wax-embedded sections. This employs a monoclonal antibody whch is raised against purified EGFR and does not crossreact with blood group antigens. This cross-reaction has been shown to be a problem with some previously described immunohistochemical assays for EGFR (Gerdin et al., 1992) . The pattern of staining produced by this assay is consistent with the known distribution of EGFR in breast tissues, both benign and malignant, and also in other normal components of these sections such as skin, nerves and smooth muscle (Damjanov et al., 1986) . It has the significant advantage over LBA/EIA of showing the tissue distribution of the EGFR, eliminating the problem of possible confounding of results by expression in normal breast epithelium (and other tissue elments). Benign breast epithelium has been previously shown to express higher mean levels of EGFR than malignant breast epithelium by both LBA and immunohistochemistry on frozen material (Travers et al., 1988; Barker et al., 1989; Dittadi et al., 1993) .
The proportion of tumours staining positively by this IHA is relatively low (22%). This is at the lower end of the range of positivity rates found in other studies (14-91% for a variety of assay methods, 14-65% for immunohistochemical analyses using the EGFR1 antibody on frozen tissue; Klijn et al., 1992) . Our positivity rate may be within the expected variability range found when comparing results across several often relatively small studies. Alternatively, it may relate to the assay method in which antigen retrieval in the form of protease digestion is essential. The length of the digestion phase of the protocol is limited by the need to preserve tissue morphology. It (IHA) showed the expected inverse association with ER while EGFR (LBA-20) did not (Table I) . EGFR did show a significant inverse correlation, but the relationship was not as strong as that with the IHA ( = 8.3 vs = 24.9) . No association was seen between nodal status and EGFR measured by either method. In terms of prognosis, (Table II) EGFR (IHA) was a significant factor (on univariate analysis) for both RFS and OS and retained significance on multivariate analysis for RFS (P<0.01). EGFR (LBA-20 or -38) was not a significant prognostic factor for either RFS or OS.
The data on comparability are thus very encouraging, indicating that the IHA is likely to be at least as useful as the LBA for clinical assessment of EGFR. The statistically stronger relationships with EGFR(IHA) may be due to the exclusion by this approach of EGFR-expressing normal benign tissue, which would be expected to be biologically less relevant (or entirely irrelevant) in relation to disease progression. Confirmation of the prognostic significance of EGFR(IHA) would obviously require a much larger patient group. Such a study is planned for the near future.
In conclusion, we have developed and validated an immunohistochemical assay for EGFR which is quick and simple to perform, requires small amounts of tissue and can be applied to paraffin-embedded sections and thus to archival matenal.
